An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Hyaluronidase
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms PAVO
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Dec 2017 Updated safety, efficacy and pharmacokinetic data will be presented at the meeting.
    • 12 Dec 2017 Updated efficacy and safety results (n=78) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Updated data from Part 2 of this trial presented in a Janssen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top